{"answer":{"query":"pomalyst","resolved_as":"name","packages":8,"applications":["NDA204026"],"identity":{"application_numbers":["NDA204026"],"marketing_categories":["NDA"],"labelers":[{"text":"CELGENE CORPORATION","untrusted":true}],"dosage_forms":[{"text":"CAPSULE","untrusted":true}],"marketing_start":{"earliest":"2013-02-18","latest":"2013-02-18","packages_with_a_start_date":8}},"price":{"median_negotiated_over_nadac":null,"packages_compared":0,"packages_listed":8,"negotiated_price_ends":null,"rows":[{"ndc":"59572050100","name":{"text":"POMALYST (POMALIDOMIDE) 1mg, 100 caps/Bottle","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"59572050121","name":{"text":"POMALYST (POMALIDOMIDE) 1mg, 21 caps/Bottle","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"59572050200","name":{"text":"POMALYST (POMALIDOMIDE) 2mg, 100 caps/Bottle","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"59572050221","name":{"text":"POMALYST (POMALIDOMIDE) 2mg, 21 caps/Bottle","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"59572050300","name":{"text":"POMALYST (POMALIDOMIDE) 3mg, 100 caps/Bottle","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"59572050321","name":{"text":"POMALYST (POMALIDOMIDE) 3mg, 21 caps/Bottle","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"59572050400","name":{"text":"POMALYST (POMALIDOMIDE) 4mg, 100 caps/Bottle","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"59572050421","name":{"text":"POMALYST (POMALIDOMIDE) 4mg, 21 caps/Bottle","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null}],"negotiated_scheduled":{"thirty_day":8650,"effective":"2027-01-01"}},"generic_entry":[{"application":"NDA204026","date":"2031-12-21","reading":"upper bound from listed dates, not a forecast","basis":"latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled)","driver":{"kind":"patent","ref":"8828427*PED","productNo":"001"},"latest_patent_expiry":"2031-12-21","latest_exclusivity_expiry":"2027-11-14","dated_barriers":36,"undated_barriers":0,"orange_book_edition":"2026-09","patents_listed":3,"exclusivities_listed":3,"fact_id":"e80ef549210625135137d535"}],"label_history":{"events_total":26,"non_cmc_events":25,"counts_by_class":{"REMS":11,"LABELING":10,"EFFICACY":4},"cmc_events":1,"recent_non_cmc_events":[{"application":"NDA204026","submission_no":35,"class_code":"REMS","class_description":{"text":"REMS","untrusted":true},"status":"AP","date":"2026-04-27","documents":[{"type":"Letter","date":"2026-05-01","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/204026Orig1s035ltr.pdf","untrusted":true}}],"fact_id":"aa6dea584fea08ea21dbace3"},{"application":"NDA204026","submission_no":34,"class_code":"REMS","class_description":{"text":"REMS","untrusted":true},"status":"AP","date":"2025-02-26","documents":[{"type":"Letter","date":"2025-02-27","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/204026Orig1s034ltr.pdf","untrusted":true}},{"type":"Label","date":"2025-02-27","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/204026s034lbl.pdf","untrusted":true}}],"fact_id":"f62e5796b44b289c0299059b"},{"application":"NDA204026","submission_no":31,"class_code":"REMS","class_description":{"text":"REMS","untrusted":true},"status":"AP","date":"2023-03-24","documents":[{"type":"Letter","date":"2023-03-27","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/204026Orig1s031ltr.pdf","untrusted":true}},{"type":"Label","date":"2023-03-27","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204026s031lbl.pdf","untrusted":true}}],"fact_id":"4f323ffbd162b9c68d0a34bf"},{"application":"NDA204026","submission_no":29,"class_code":"REMS","class_description":{"text":"REMS","untrusted":true},"status":"AP","date":"2021-08-05","documents":[{"type":"Letter","date":"2021-08-09","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/204026Orig1s029ltr.pdf","untrusted":true}}],"fact_id":"18671b7861ccb67c0d3531c1"},{"application":"NDA204026","submission_no":28,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2020-12-03","documents":[{"type":"Label","date":"2020-12-03","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204026s028lbl.pdf","untrusted":true}},{"type":"Letter","date":"2020-12-07","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/204026Orig1s028ltr.pdf","untrusted":true}}],"fact_id":"b3176d268b0ef0f52d94525a"}],"note":"a dated list of FDA supplements and their classes, not a reading of what changed in the label"},"substitution":{"products_total":4,"te_code_counts":{"AB":4},"marketing_status_counts":{"Prescription":4},"meaning":"raw FDA codes; the therapeutic equivalence code says whether FDA rates a generic as substitutable, and what that means for a given prescription is for a pharmacist or prescriber","products":[{"application":"NDA204026","product_no":"003","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"POMALYST","untrusted":true},"form":{"text":"CAPSULE;ORAL","untrusted":true},"strength":{"text":"3MG","untrusted":true}},{"application":"NDA204026","product_no":"004","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"POMALYST","untrusted":true},"form":{"text":"CAPSULE;ORAL","untrusted":true},"strength":{"text":"4MG","untrusted":true}},{"application":"NDA204026","product_no":"002","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"POMALYST","untrusted":true},"form":{"text":"CAPSULE;ORAL","untrusted":true},"strength":{"text":"2MG","untrusted":true}},{"application":"NDA204026","product_no":"001","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"POMALYST","untrusted":true},"form":{"text":"CAPSULE;ORAL","untrusted":true},"strength":{"text":"1MG","untrusted":true}}]},"recalls":{"recalls_total":1,"counts_by_class":{"Class II":1},"packages_of_these_applications":8,"most_recent":[{"recall_number":"D-0768-2018","classification":"Class II","status":"Terminated","report_date":"2018-05-16","recall_initiated":"2018-04-03","recalling_firm":{"text":"Kroger Specialty Pharmacy, Inc.","untrusted":true},"reason":{"text":"Lack of Processing Controls.","untrusted":true},"packages_named":1,"fact_id":"08f4f7d6230b804fe4732db5"}],"meaning":"FDA classifies the health hazard of a recall, not its effect on supply"},"trials":{"attribution":"Source: ClinicalTrials.gov","modification_statement":"OmniRx has summarized and trimmed this ClinicalTrials.gov data.","not_an_offer":"A recruiting trial listing is not an offer of free drug and not medical advice; enrollment is decided by the study team.","ingredients":[{"ingredient":{"text":"POMALIDOMIDE","untrusted":true},"recruiting_interventional_count":57,"not_yet_recruiting_count":13,"by_phase":{"PHASE3":16,"PHASE1":9,"PHASE2":15,"PHASE1/PHASE2":13,"NA":3,"PHASE2/PHASE3":1},"registry_processing_date":"2026-11-06T10:00:05","modifications":"Counts and phase tallies computed here from the full recruiting result set; trials trimmed to the 25 most recently updated, conditions to 3, countries to 10 distinct; no text edited.","recent_trials":[{"nct_id":"NCT05730036","title":{"text":"A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma","untrusted":true},"phase":["PHASE3"],"sponsor":{"text":"Regeneron Pharmaceuticals","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-06","start_date":"2023-09-18","link":{"text":"https://clinicaltrials.gov/study/NCT05730036","untrusted":true}},{"nct_id":"NCT05137054","title":{"text":"A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments","untrusted":true},"phase":["PHASE1"],"sponsor":{"text":"Regeneron Pharmaceuticals","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-05","start_date":"2022-08-17","link":{"text":"https://clinicaltrials.gov/study/NCT05137054","untrusted":true}},{"nct_id":"NCT07825064","title":{"text":"Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma","untrusted":true},"phase":["PHASE2"],"sponsor":{"text":"Hoffmann-La Roche","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-05","start_date":"2026-11-03","link":{"text":"https://clinicaltrials.gov/study/NCT07825064","untrusted":true}},{"nct_id":"NCT06948084","title":{"text":"Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse","untrusted":true},"phase":["PHASE2"],"sponsor":{"text":"National Cancer Institute (NCI)","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-04","start_date":"2027-05-22","link":{"text":"https://clinicaltrials.gov/study/NCT06948084","untrusted":true}},{"nct_id":"NCT07222761","title":{"text":"A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","untrusted":true},"phase":["PHASE3"],"sponsor":{"text":"Regeneron Pharmaceuticals","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-04","start_date":"2026-01-02","link":{"text":"https://clinicaltrials.gov/study/NCT07222761","untrusted":true}}],"fact_id":"eb56705a0af30bb86a912bfe"}]},"spending":{"reported_under":{"generic":{"text":"Pomalidomide","untrusted":true},"brand":{"text":"Pomalyst","untrusted":true}},"latest_year":2024,"series":[{"year":2020,"gross_spending_usd":1453860766.6,"claims":79081,"beneficiaries":12067,"average_spending_per_claim_usd":18384.450962,"fact_id":"99422e5fd0427f99526f957e"},{"year":2021,"gross_spending_usd":1595079244.8,"claims":82854,"beneficiaries":12596,"average_spending_per_claim_usd":19251.686639,"fact_id":"80cc952cca4595ea672d5274"},{"year":2022,"gross_spending_usd":1743892720.4,"claims":86195,"beneficiaries":12682,"average_spending_per_claim_usd":20231.947566,"fact_id":"210c163814593816e99db910"},{"year":2023,"gross_spending_usd":1709288465.2,"claims":78733,"beneficiaries":12739,"average_spending_per_claim_usd":21709.936942,"fact_id":"8ad6074788a122ff081dc3ea"},{"year":2024,"gross_spending_usd":2150231814.6,"claims":98648,"beneficiaries":14325,"average_spending_per_claim_usd":21797.013772,"fact_id":"20f00fe50ad8eb4d92e34a89"}],"rebate_caveat":"CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions.","not_a_patient_price":"Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.","meaning":"a drug-level aggregate of Medicare Part D claims for all manufacturers combined; not a formulary, not coverage","source":{"dataset":{"text":"data-year-2024, modified 2026-06-25","untrusted":true},"link":{"text":"https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-d-spending-by-drug","untrusted":true}}},"rems":{"programs":[{"application":"NDA204026","program":{"text":"PS-Pomalidomide","untrusted":true},"rems_id":"435","in_force":true,"released":false,"moved_to_shared_system":false,"has_etasu":true,"program_date":"2025-02-26","last_modified":"2026-04-27","source_page":"https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=IndvRemsDetails.page&REMS=435","other_programs":1,"read_on":"2026-11-07T20:05:28.959Z","fact_id":"c373a5bf5056c91eeb78a914"}],"reading":"what the FDA REMS@FDA files tie to the application on the read date; it does not say which prescribers or pharmacies take part or whether a patient needs the program"},"orphan_designation":{"ingredients":[{"ingredient":{"text":"pomalidomide","untrusted":true},"designation_count":4,"approved_count":2,"recent":[{"designated":"2018-04-04","use":{"text":"Treatment of Kaposi sarcoma","untrusted":true},"status":"Designated/Approved","sponsor":{"text":"Celgene Corporation","untrusted":true},"approved":true},{"designated":"2013-08-22","use":{"text":"Treatment of systemic sclerosis","untrusted":true},"status":"Designated/Designation Withdrawn or Revoked","sponsor":{"text":"Celgene Corporation","untrusted":true},"approved":false},{"designated":"2010-09-21","use":{"text":"Treatment of persons with myeloproliferative neoplasm-associated myelofibrosis and anemia who are red blood cell tranfusion dependent.","untrusted":true},"status":"Designated/Designation Withdrawn or Revoked","sponsor":{"text":"Celgene Corporation","untrusted":true},"approved":false},{"designated":"2003-01-15","use":{"text":"Treatment of multiple myeloma","untrusted":true},"status":"Designated/Approved","sponsor":{"text":"Celgene Corporation","untrusted":true},"approved":true}],"read_on":"2026-11-07T12:00:00.000Z","fact_id":"2ddf6c684e803753bcffa07b"}],"reading":"a designation is not an approval and not a statement that the drug treats the condition; status is the FDA database's own"},"medicaid_state_utilization":{"year":2025,"states_with_data":3,"all_states_medicaid_reimbursed_usd":4154424.8,"all_states_medicaid_paid_prescriptions":208,"top_states":[{"state":"OH","medicaid_paid_prescriptions":65,"medicaid_reimbursed_usd":1434600.85,"total_reimbursed_usd":1458016.4,"packages":1,"covers":"fee_for_service_only","fact_id":"2ed99c237b024f331d681acf"},{"state":"OR","medicaid_paid_prescriptions":62,"medicaid_reimbursed_usd":1379936.96,"total_reimbursed_usd":1379936.96,"packages":1,"covers":"all_record_types","fact_id":"0c3ce2f0f3bbcb5f0ccc1235"},{"state":"IL","medicaid_paid_prescriptions":81,"medicaid_reimbursed_usd":1339886.99,"total_reimbursed_usd":1339886.99,"packages":1,"covers":"fee_for_service_only","fact_id":"e468d26ec523efc1f6aa4ce9"}],"unlabelled_state_code_xx":null,"built_from_facts":3,"facts_fee_for_service_only":2,"older_year_facts_not_used":23,"dataset":"State Drug Utilization Data 2025","read_on":"2026-11-07T22:41:44.201Z","reading":"Medicaid prescriptions and reimbursement by state (CMS State Drug Utilization Data). Reimbursement is before manufacturer rebates: not a net cost, not a patient price. Suppressed managed-care cells make a state figure fee-for-service only. An absent state was suppressed or unreported, not zero.","receipts_note":"a receipt is held for the largest fact behind each state shown; every figure is a sum of the built_from_facts facts, each recomputable from its recorded input hash"}},"receipts":[{"fact_id":"47e017172e6c173072d0a166","field":"ndc.listing","entity":"ndc:59572050100"},{"fact_id":"410976787879452bf3789622","field":"ndc.listing","entity":"ndc:59572050121"},{"fact_id":"8a038c8d66708643b3152cf3","field":"ndc.listing","entity":"ndc:59572050200"},{"fact_id":"e80ef549210625135137d535","field":"drug.generic_entry_earliest","entity":"application:NDA204026"},{"fact_id":"0bedeb40da69eca052a2862e","field":"drug.patent","entity":"application:NDA204026"},{"fact_id":"07be01cacfbacc88d269b8fa","field":"drug.exclusivity","entity":"application:NDA204026"},{"fact_id":"aa6dea584fea08ea21dbace3","field":"drug.label_event","entity":"application:NDA204026"},{"fact_id":"f62e5796b44b289c0299059b","field":"drug.label_event","entity":"application:NDA204026"},{"fact_id":"4f323ffbd162b9c68d0a34bf","field":"drug.label_event","entity":"application:NDA204026"},{"fact_id":"18671b7861ccb67c0d3531c1","field":"drug.label_event","entity":"application:NDA204026"},{"fact_id":"b3176d268b0ef0f52d94525a","field":"drug.label_event","entity":"application:NDA204026"},{"fact_id":"ee192bc3c08ace1038571545","field":"drug.te_code","entity":"application:NDA204026"},{"fact_id":"efa6befb9ae79e7a3f5f477a","field":"drug.marketing_status","entity":"application:NDA204026"},{"fact_id":"b1dd7febc3efa551c871752d","field":"drug.te_code","entity":"application:NDA204026"},{"fact_id":"7c4998ce6afd19ddccd21cd9","field":"drug.marketing_status","entity":"application:NDA204026"},{"fact_id":"a9b48d29c5ea82c89cd839cd","field":"drug.te_code","entity":"application:NDA204026"},{"fact_id":"41b3c94d46088d63122e110b","field":"drug.marketing_status","entity":"application:NDA204026"},{"fact_id":"9731034d0f93d38e6042b6f0","field":"drug.te_code","entity":"application:NDA204026"},{"fact_id":"0b9114c28d2adc17c1dc4351","field":"drug.marketing_status","entity":"application:NDA204026"},{"fact_id":"08f4f7d6230b804fe4732db5","field":"ndc.recall","entity":"ndc:59572050321"},{"fact_id":"eb56705a0af30bb86a912bfe","field":"drug.trial_access","entity":"drug:pomalidomide"},{"fact_id":"99422e5fd0427f99526f957e","field":"drug.partd_spending","entity":"drug:pomalidomide|pomalyst"},{"fact_id":"80cc952cca4595ea672d5274","field":"drug.partd_spending","entity":"drug:pomalidomide|pomalyst"},{"fact_id":"210c163814593816e99db910","field":"drug.partd_spending","entity":"drug:pomalidomide|pomalyst"},{"fact_id":"8ad6074788a122ff081dc3ea","field":"drug.partd_spending","entity":"drug:pomalidomide|pomalyst"},{"fact_id":"20f00fe50ad8eb4d92e34a89","field":"drug.partd_spending","entity":"drug:pomalidomide|pomalyst"},{"fact_id":"c373a5bf5056c91eeb78a914","field":"drug.rems","entity":"application:NDA204026"},{"fact_id":"2ddf6c684e803753bcffa07b","field":"drug.orphan_designation","entity":"drug:pomalidomide"},{"fact_id":"2ed99c237b024f331d681acf","field":"ndc.medicaid_state_utilization","entity":"ndc_state:59572050321:OH"},{"fact_id":"0c3ce2f0f3bbcb5f0ccc1235","field":"ndc.medicaid_state_utilization","entity":"ndc_state:59572050221:OR"},{"fact_id":"e468d26ec523efc1f6aa4ce9","field":"ndc.medicaid_state_utilization","entity":"ndc_state:59572050421:IL"}],"as_of":{"newest_fact_retrieved_at":"2026-11-10T20:02:39.475Z"},"edition":{"id":"2026-11","merkleRoot":"006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6","factCount":212100,"manifestPresent":true},"licence":{"classes":["AMBER","GREEN"],"note":"Source records are public; this compilation is cited with attribution. See the provenance tool for each fact's licence label."},"unknown":[{"code":"NO_DATA","field":"price.ratio","reason":"no package has both a brand-class NADAC price and a negotiated price in force"},{"code":"NO_DATA","field":"supply","reason":"no FDA shortage row and no termination date for these packages"},{"code":"NO_DATA","field":"assistance_and_offers","reason":"no assistance program lists this drug and no manufacturer offer naming it is recorded; that does not mean none exists"},{"code":"NO_DATA","field":"policy","reason":"no Federal Register event in the edition names this drug or its programs"},{"code":"NO_DATA","field":"biologic_status","reason":"no biologic application of this drug has a Purple Book status in the edition (a drug that is not a biologic has none)"},{"code":"NO_DATA","field":"payment_limit","reason":"no HCPCS code whose NDC crosswalk names a package of these applications has a Part B payment limit in the edition"},{"code":"NO_DATA","field":"controlled_schedule","reason":"no DEA schedule entry matched this drug's ingredient in the edition"},{"code":"NO_DATA","field":"safety_communication","reason":"no FDA Drug Safety Communication names this drug's ingredient in the edition"}],"disclaimer":"OmniRx is a reference layer of dated public facts, not clinical advice and not a guarantee of price, coverage or eligibility. Each answer lists the facts it rests on."}